Latest Articles

Publication Date
Achieving Minimal-to-No Pain in Women with Endometriosis Treated with Relugolix Combination Therapy: SPIRIT Extension Trial.

Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometriosis symptoms while …

Published: Sept. 5, 2026, midnight
Combined pelvic floor training and hormonal therapy for endometriosis pain recurrence: a propensity score-matched study.

Endometriosis (EMS) causes debilitating pain and reduces quality of life. Whether pelvic floor muscle training (PFMT) provides independent, additive benefits beyond standard postoperative hormonal suppression remains unknown.

Published: Aug. 31, 2026, midnight
Precise Surgical Navigation of Endometriosis via NIR-II Fluorescence Imaging With a Semiconducting Polymeric Probe.

Endometriosis is a prevalent gynecological disorder characterized by ectopic growth of endometrial-like tissue, often causing chronic pain, infertility, and systemic inflammation. Accurate detection and complete surgical resection remain challenging because …

Published: Aug. 24, 2026, midnight
Endometriosis-associated bone loss: re-evaluating the potential role of systemic inflammation and hypoestrogenic therapies.

Endometriosis is frequently managed with hormonal suppression that can induce hypoestrogenism during a period when many patients are still accruing peak bone mass. This narrative review summarizes current clinical and …

Published: Aug. 19, 2026, midnight
Dual Intrauterine Device Placement for Refractory Endometriosis Pain in a Bicornuate Uterus: A Case Report.

A 27-year-old nulliparous woman presented with chronic pelvic pain (CPP) (8/10 on the Numerical Rating Scale (NRS)), dysmenorrhea, heavy menstrual bleeding (HMB), and a family history of endometriosis. She had …

Published: Aug. 17, 2026, midnight
Role of oral gonadotropin-releasing hormone antagonists in the management of uterine adenomyosis: a narrative review.

In women with uterine adenomyosis, bleeding and pain can have a major impact on quality of life. There is clearly widespread demand for effective long-term medical therapies. The objective of …

Published: Aug. 14, 2026, midnight
Adolescent dysmenorrhea revealing Herlyn-Werner-Wunderlich syndrome with endometriosis: A radiologic case report.

Herlyn-Werner-Wunderlich syndrome, also referred to as obstructed hemivagina with ipsilateral renal agenesis (OHVIRA) is a rare congenital urogenital anomaly resulting from abnormal development of the Müllerian and Wolffian ducts, classically …

Published: Aug. 14, 2026, midnight
Hormonal therapies for endometriosis-associated pain: inflammatory limitations and pharmacological challenges.

Endometriosis is a chronic inflammatory and estrogen-dependent disease in which pain remains the leading cause of impaired quality of life. Hormonal therapies constitute the cornerstone of medical management and include …

Published: Aug. 11, 2026, midnight
Endometriosis and long-term risk of venous thromboembolism: a Danish nationwide study.

Endometriosis affects ∼10% of women of reproductive age. Emerging evidence suggests a link between endometriosis and systemic inflammation, potentially increasing the risk of venous thromboembolism (VTE), yet data on the …

Published: Aug. 8, 2026, midnight
Endometrial cells with high ALDH activity contribute to uterine development and regeneration.

Adult stem cells are thought to drive the regenerative potential of the endometrium and contribute to the pathogenesis of endometriosis; however, their identity and defining features remain to be characterized. …

Published: Aug. 6, 2026, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!